US20210169865A1

Combination of bcl-2 inhibitor and mek inhibitor for the treatment of cancer

University of Texas System

Abstract

The present invention is directed to a combination therapy involving a selective Bcl-2 inhibitor and a MEK inhibitor for the treatment of a patient in need of such a therapy. The patient in need of the combination therapy is suffering from cancer, such as acute myeloid leukemia.

University: University of Texas System
Assignee: Board Of Regents, The University Of Texas System
Inventor: Mark Merchant
Priority date: November 03, 2015
Filing date: February 18, 2021
Publication date: June 10, 2021
Language: en
PDF source: https://patentimages.storage.googleapis.com/3d/f5/a3/afcc45127adbbd/US20210169865A1.pdf
Metadata fetched: August 29, 2026 00:28